A Parallel-Arm Phase 1b/2a Study of DKN-01 as Monotherapy or in Combination With Docetaxel for the Treatment of Advanced Prostate Cancer With Elevated DKK1

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Prostate Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male
  • Other Inclusion Criteria:
    1. Patient has histologically confirmed prostate adenocarcinoma. 2. Patient has been surgically or medically castrated 3. DKN-01 + Docetaxel Cohort: Patients must have received 1 or more androgen receptor (AR) signaling inhibitors (abiraterone or enzalutamide) and ha e not received prior docetaxel or cabazitaxel. 4. DKN-01 Monotherapy Cohort: Patients must have received 1 or more AR inhibitor and have received docetaxel or cabazitaxel. Patients who are intolerant of or refusing docetaxel or cabazitaxel will be eligible. 5. Patient with high levels of DKK1

You may not be eligible for this study if the following are true:

  • 1. Histological small cell or pure neuroendocrine carcinoma that has not yet been treated with at least one line of platinum-based chemotherapy 2. Any anti-cancer therapy (with the exception of luteinizing hormone-releasing hormone [LHRH] analog or antagonist) within 2 weeks prior to initiation of study treatment. 3. Any investigational anti-cancer therapy within 4 weeks of initiation of study treatment.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.